skip to main content
UTRGV The University of Texas Rio Grande Valley
Main Menu
Donate Now Directory myUTRGV

You are here:

Home News Dr. Mario Gil awarded NIH K01 Grant
EspaƱol

Alzheimer's Disease Resource Center for Minority Aging Research UTRGV School of Medicine

  • Home
  • Research Cores
    • Administrative Core
      • Reporting AD-RCMAR Activities
    • Analysis Core
    • Community Liaison & Recruitment Core
    • Research Education Component
      • Pilot Studies Program
  • RCMAR Scientists
  • Ongoing Pilot Studies
  • AD-RCMAR Affiliate Program
  • Resources
    • Neuroscience Research Seminars
      • Alzheimer's and Related Dementias
      • Brain Equity
      • Social Determinants of Health
      • Past Speakers
  • Publications

Contact Us

Gladys E. Maestre, MD, PhD
Director
Email: Gladys.Maestre@utrgv.edu
Phone: (956) 882-7594
Fax: (956) 665-9797

Quick Links

  • What is Alzheimer's Disease?
  • Learn about RCMARs and Research Resources
  • Funding Opportunities
  • News
  • Events

Dr. Mario Gil awarded NIH K01 Grant

Dr. Mario Gil awarded an NIH K01 grant to study heart regulating systems that underlie neural regulation of psychosocial stress responses

Dr. Mario Gil, assistant professor at the UTRGV Department of Psychological Sciences and one of our RGV AD-RCMAR Scientist was awarded a K01 grant to test the hypothesis that Avpr1a V1AR gene expression patterns predict arginine-vasopressin effects on psychosocial-stress in an animal myocardial ischemia-reperfusion injury model.

The purpose of the NIH K01 program is to provide support and protected time for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Some NIH Institutes use the K01 to enhance workforce diversity, or for individuals who propose to train in a new field, or for individuals who have had a hiatus in their research careers.

This K01 grant stems from Dr. Gil’s pilot research at the RGV AD-RCMAR, where he focused on the neurobiology of social behavior and social stressors in older Hispanics. The proposed study will explore the therapeutic potential of arginine-vasopressin, acting via the V1A receptor, in treating stress-associated cardiovascular conditions.

We congratulate Dr. Gil for this award, and we hope this project will open more research opportunities for him and strengthen his career in minority aging research.

Gladys E. Maestre, MD, PhD.
Director, RGV AD-RCMAR


Jump to Top

UTRGV

  • Twitter
  • Facebook
  • LinkedIn
  • YouTube
  • CARES, CRRSAA and ARP Reporting
  • Site Policies
  • Contact UTRGV
  • Required Links
  • Fraud Reporting
  • Senate Bill 18 Reporting
  • UTRGV Careers
  • Clery Act Reports
  • Web Accessibility
  • Mental Health Resources
  • Sexual Misconduct Policy
  • Reporting Sexual Misconduct